What question did this study set out to answer?

This research aims to identify a novel Nrf2 activator that can suppress osteoclastogenesis and treat osteoporosis-related bone loss.

A Novel Nrf2 Activator Suppresses Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Directly Interfering Keap1-Nrf2 Protein–Protein Interaction

View Full Paper

Ask AI

Bookmark

Authors

Animal study shows a novel Nrf2 activator reduces bone loss in osteoporosis, suggesting a new treatment approach.

This research aims to identify a novel Nrf2 activator that can suppress osteoclastogenesis and treat osteoporosis-related bone loss.
Synthesis of a series of 5-selenyl-flavone compounds
In vitro testing of these compounds on RANKL-induced osteoclastogenesis
In vivo testing in a mouse model of osteoporosis
Compound 5c was the most effective in inhibiting osteoclast formation and resorption activity
5c decreased expression levels of osteoclast-specific genes and proteins
5c noncovalently bound to Keap1, disrupting the Keap1-Nrf2 interaction

Huang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark